A clinical trial supports our study finding where administration of ustekinumab, an anti-IL-23A monoclonal antibody, or brodalumab, or anti-IL-17A blockers resulted in a significant reduction of anxiety and depression symptoms in psoriasis patients54,55. This evidence concerns the gene IL23A and psoriasis.